115563
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.6 Breast Cancer (Dove Med Press)
- 4.3 Clin Epidemiol
- 2.6 Cancer Manag Res
- 3.2 Infect Drug Resist
- 4.1 Clin Interv Aging
- 6.1 Drug Des Dev Ther
- 4.1 Int J Chronic Obstr
- 8.7 Int J Nanomed
- 2.5 Int J Women's Health
- 3.2 Neuropsych Dis Treat
- 2.4 OncoTargets Ther
- 2.6 Patient Prefer Adher
- 2.6 Ther Clin Risk Manag
- 3.1 J Pain Res
- 3.5 Diabet Metab Synd Ob
- 4.5 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 2.4 Pharmgenomics Pers Med
- 2.6 Risk Manag Healthc Policy
- 4.6 J Inflamm Res
- 2.3 Int J Gen Med
- 3.9 J Hepatocell Carcinoma
- 3.3 J Asthma Allergy
- 2.5 Clin Cosmet Investig Dermatol
- 3.0 J Multidiscip Healthc
已发表论文
肥厚型心肌病中泛凋亡相关生物标志物的鉴定：多组学分析的见解
Authors Zhong J, Zhao Q, Wu R, Zhang S, Liu G, Zhang Z, Han X, Shi L
Received 22 July 2025
Accepted for publication 8 December 2025
Published 7 January 2026 Volume 2026:19 555505
DOI https://doi.org/10.2147/JIR.S555505
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Dr Qing Lin
Jinlong Zhong,1 Qinghui Zhao,2 Ruiqing Wu,3 Shuguang Zhang,4 Guoyi Liu,5 Zhihui Zhang,6 Xia Han,7 Lin Shi1,8
1Department of Pathology, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, People’s Republic of China; 2Department of Medical Engineering, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, People’s Republic of China; 3Department of Cardiology, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, People’s Republic of China; 4Department of Forensic Medicine, Inner Mongolia Medical University, Hohhot, People’s Republic of China; 5Public Security Sub-Bureau of Xincheng District, Hohhot, People’s Republic of China; 6Central Laboratory, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, People’s Republic of China; 7Stem Cell Laboratory, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, People’s Republic of China; 8Inner Mongolia Medical University, Hohhot, People’s Republic of China
Correspondence: Lin Shi, Email ShiLin050906@126.com
Background: Hypertrophic cardiomyopathy (HCM) is a common inherited cardiomyopathy characterized by ventricular hypertrophy, fibrosis, and increased risk of sudden cardiac death. However, the underlying molecular pathways contributing to its progression remain incompletely defined. PANoptosis, a newly defined inflammatory form of programmed cell death integrating pyroptosis, apoptosis, and necroptosis, has been implicated in cardiac injury and may represent a convergent mechanism linking inflammation and myocardial remodeling, but remains uninvestigated in HCM.
Methods: Transcriptomic profiles from HCM and control hearts were analyzed to identify differentially expressed PANoptosis-related genes. A nine-gene diagnostic panel was constructed using a comprehensive multi-algorithm machine learning framework integrating ensemble, kernel-based, and regularized regression models, and validated in external cohorts. Molecular subtypes were identified through consensus clustering. Immune infiltration, functional enrichment, and ceRNA regulatory networks were evaluated. Single-nucleus RNA sequencing localized gene expression to specific cardiac cell types. Cell–cell communication analysis explored intercellular signaling. Experimental validation was performed in a murine HCM model using echocardiography, histology, and RT-qPCR. Molecular docking assessed therapeutic potential of candidate compounds. Finally, molecular docking and target prediction were applied to explore potential therapeutic compounds acting on the PANoptosis axis.
Results: Nine PANoptosis-related genes (S100A9, GADD45A, IER3, STAT3, SFRP1, PHLDA1, JAK2, MYC, S100A8) showed high diagnostic performance (AUC > 0.95). Two molecular subtypes displayed distinct immune and metabolic signatures. PANoptosis genes correlated with T cells, macrophages, and dendritic cells. CellChat analysis revealed PDGF-mediated signaling between cardiomyocytes and fibroblasts. Key genes exhibited cell-type–specific expression. In vivo validation confirmed gene expression trends. Moreover, folic acid and tretinoin exhibited favorable docking affinity with core targets, suggesting potential therapeutic relevance.
Conclusion: This study provides the first systematic evidence linking PANoptosis to the molecular pathogenesis of HCM. PANoptosis contributes to HCM pathogenesis and immune remodeling, and the identified biomarkers demonstrate translational potential as diagnostic indicators and therapeutic targets. The integrated analysis highlights novel PANoptotic signaling axes that may guide future precision diagnosis and intervention strategies for HCM.
Keywords: hypertrophic cardiomyopathy, PANoptosis, diagnostic biomarkers, machine learning
1Department of Pathology, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, People’s Republic of China; 2Department of Medical Engineering, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, People’s Republic of China; 3Department of Cardiology, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, People’s Republic of China; 4Department of Forensic Medicine, Inner Mongolia Medical University, Hohhot, People’s Republic of China; 5Public Security Sub-Bureau of Xincheng District, Hohhot, People’s Republic of China; 6Central Laboratory, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, People’s Republic of China; 7Stem Cell Laboratory, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, People’s Republic of China; 8Inner Mongolia Medical University, Hohhot, People’s Republic of China
Correspondence: Lin Shi, Email ShiLin050906@126.com
Background: Hypertrophic cardiomyopathy (HCM) is a common inherited cardiomyopathy characterized by ventricular hypertrophy, fibrosis, and increased risk of sudden cardiac death. However, the underlying molecular pathways contributing to its progression remain incompletely defined. PANoptosis, a newly defined inflammatory form of programmed cell death integrating pyroptosis, apoptosis, and necroptosis, has been implicated in cardiac injury and may represent a convergent mechanism linking inflammation and myocardial remodeling, but remains uninvestigated in HCM.
Methods: Transcriptomic profiles from HCM and control hearts were analyzed to identify differentially expressed PANoptosis-related genes. A nine-gene diagnostic panel was constructed using a comprehensive multi-algorithm machine learning framework integrating ensemble, kernel-based, and regularized regression models, and validated in external cohorts. Molecular subtypes were identified through consensus clustering. Immune infiltration, functional enrichment, and ceRNA regulatory networks were evaluated. Single-nucleus RNA sequencing localized gene expression to specific cardiac cell types. Cell–cell communication analysis explored intercellular signaling. Experimental validation was performed in a murine HCM model using echocardiography, histology, and RT-qPCR. Molecular docking assessed therapeutic potential of candidate compounds. Finally, molecular docking and target prediction were applied to explore potential therapeutic compounds acting on the PANoptosis axis.
Results: Nine PANoptosis-related genes (S100A9, GADD45A, IER3, STAT3, SFRP1, PHLDA1, JAK2, MYC, S100A8) showed high diagnostic performance (AUC > 0.95). Two molecular subtypes displayed distinct immune and metabolic signatures. PANoptosis genes correlated with T cells, macrophages, and dendritic cells. CellChat analysis revealed PDGF-mediated signaling between cardiomyocytes and fibroblasts. Key genes exhibited cell-type–specific expression. In vivo validation confirmed gene expression trends. Moreover, folic acid and tretinoin exhibited favorable docking affinity with core targets, suggesting potential therapeutic relevance.
Conclusion: This study provides the first systematic evidence linking PANoptosis to the molecular pathogenesis of HCM. PANoptosis contributes to HCM pathogenesis and immune remodeling, and the identified biomarkers demonstrate translational potential as diagnostic indicators and therapeutic targets. The integrated analysis highlights novel PANoptotic signaling axes that may guide future precision diagnosis and intervention strategies for HCM.
Keywords: hypertrophic cardiomyopathy, PANoptosis, diagnostic biomarkers, machine learning